Background: Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, and abrupt discontinuation can lead to severe neuropsychiatric destabilization, including withdrawal catatonia. High-potency dopamine D2 receptor antagonists may further precipitate neuroleptic malignant syndrome (NMS), a condition with substantial clinical overlap with malignant catatonia. Objective: This report follows CARE guidelines to provide a structured and transparent description of a complex case involving abrupt clozapine withdrawal and rapid antipsychotic transition. Case presentation: This report describes a male patient with schizophrenia who developed malignant catatonia with overlapping NMS features following abrupt clozapine withdrawal and initiation of fluphenazine. Conclusion: The case underscores the importance of cautious antipsychotic transitions and early recognition of catatonia and NMS.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Download PDF 
Post
